These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 21220060)

  • 1. Targeting remission by 8 weeks: when should supplementation be considered in patients with major depression treated with a specific serotonin reuptake inhibitor?
    Cooper-Kazaz R; Rigbi A; Lerer B
    Compr Psychiatry; 2011; 52(1):9-16. PubMed ID: 21220060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and acceptability of sertraline and citalopram in major depressive disorder: pragmatic randomized open-label comparison.
    Matreja PS; Badyal DK; Khosla P; Deswal RS
    Hum Psychopharmacol; 2007 Oct; 22(7):477-82. PubMed ID: 17647298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.
    Cooper-Kazaz R; Apter JT; Cohen R; Karagichev L; Muhammed-Moussa S; Grupper D; Drori T; Newman ME; Sackeim HA; Glaser B; Lerer B
    Arch Gen Psychiatry; 2007 Jun; 64(6):679-88. PubMed ID: 17548749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Faster onset of antidepressant effects of citalopram compared with sertraline in drug-naïve first-episode major depressive disorder in a Chinese population: a 6-week double-blind, randomized comparative study.
    Hsu JW; Su TP; Huang CY; Chen YS; Chou YH
    J Clin Psychopharmacol; 2011 Oct; 31(5):577-81. PubMed ID: 21869697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
    Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
    Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
    Rush AJ; Trivedi MH; Wisniewski SR; Stewart JW; Nierenberg AA; Thase ME; Ritz L; Biggs MM; Warden D; Luther JF; Shores-Wilson K; Niederehe G; Fava M;
    N Engl J Med; 2006 Mar; 354(12):1231-42. PubMed ID: 16554525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.
    Bitran S; Farabaugh AH; Ameral VE; LaRocca RA; Clain AJ; Fava M; Mischoulon D
    Int Clin Psychopharmacol; 2011 Jul; 26(4):206-12. PubMed ID: 21278577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication augmentation after the failure of SSRIs for depression.
    Trivedi MH; Fava M; Wisniewski SR; Thase ME; Quitkin F; Warden D; Ritz L; Nierenberg AA; Lebowitz BD; Biggs MM; Luther JF; Shores-Wilson K; Rush AJ;
    N Engl J Med; 2006 Mar; 354(12):1243-52. PubMed ID: 16554526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline.
    Stahl SM
    Biol Psychiatry; 2000 Nov; 48(9):894-901. PubMed ID: 11074227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L
    J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
    Azorin JM; Llorca PM; Despiegel N; Verpillat P
    Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
    Fava M; Rush AJ; Alpert JE; Balasubramani GK; Wisniewski SR; Carmin CN; Biggs MM; Zisook S; Leuchter A; Howland R; Warden D; Trivedi MH
    Am J Psychiatry; 2008 Mar; 165(3):342-51. PubMed ID: 18172020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early symptom change prediction of remission in depression treatment.
    Katz MM; Meyers AL; Prakash A; Gaynor PJ; Houston JP
    Psychopharmacol Bull; 2009; 42(1):94-107. PubMed ID: 19204654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Sertraline in Patients With Major Depressive Disorder Naive to Selective Serotonin Reuptake Inhibitors: A 10-Week Randomized, Multicenter, Placebo-Controlled, Double-Blind, Academic Clinical Trial.
    Valle-Cabrera R; Mendoza-Rodríguez Y; Robaina-García M; Ballesteros J; Cordero-Jiménez JR; Espinosa-Rodríguez NB; Sotolongo-Garcia Y; Lauria-Horner B;
    J Clin Psychopharmacol; 2018 Oct; 38(5):454-459. PubMed ID: 30106883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association analysis of SIGMAR1 with major depressive disorder and SSRI response.
    Kishi T; Yoshimura R; Okochi T; Fukuo Y; Kitajima T; Okumura T; Tsunoka T; Kawashima K; Yamanouchi Y; Kinoshita Y; Umene-Nakano W; Naitoh H; Nakamura J; Ozaki N; Iwata N
    Neuropharmacology; 2010 Jun; 58(7):1168-73. PubMed ID: 20178807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.
    Portella MJ; de Diego-Adeliño J; Ballesteros J; Puigdemont D; Oller S; Santos B; Álvarez E; Artigas F; Pérez V
    J Clin Psychiatry; 2011 Jul; 72(7):962-9. PubMed ID: 21034693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.